December 29, 1997 |
SuperGen Inc. said it won approval from the Food and Drug Administration to make in the U.S. a drug for treating a rare form of leukemia. When SuperGen had bought the drug, Nipent, from Warner-Lambert Co., in September 1996, it inherited the right to sell it but needed FDA approval for its manufacture. Nipent, known chemically as pentostatin, is used to treat hairy-cell leukemia, a rare blood disease that strikes mostly men, causes severe anemia and enlarges the spleen.
January 4, 2005
* Alberto-Culver Co., the world's No. 1 seller of hair products to salons, said it bought beauty products distributor CosmoProf of Chatsworth to expand into Los Angeles and Hawaii. Terms weren't disclosed. * SuperGen Inc., the Dublin, Calif.-based maker of the Nipent leukemia drug, said it withdrew a U.S. application to sell a pancreatic cancer medicine because regulators indicated that they would reject it.
June 18, 1998 |
NeoTherapeutics Inc. said it has named four new directors, boosting the board's size to nine from five. The Irvine biotechnology company said Eric L. Nelson, a member of the company's scientific advisory board; Stephen Runnels, executive vice president of the company; and Samuel Gulko, chief financial officer of the company, were elected to two-year terms. Joseph Rubinfeld, chief executive of SuperGen Inc., was elected to a one-year term on the board.
January 14, 2000 |
Techniclone Corp., a Tustin developer of cancer treatments, said Thursday that it has tentatively agreed to license one of its technologies to a San Ramon, Calif., company for about $8 million. The price includes an upfront payment, certain future payments and a royalty. Techniclone said in a press release that SuperGen Inc. will license its Vascular Targeting Agent technology, which is a therapeutic treatment designed specifically to destroy vascular tumors.
April 9, 1997
Larry Ellison, chairman of software company Oracle Corp., on Tuesday purchased a 9% stake in drug company SuperGen Inc., which is working to develop a new generation of cancer drugs. Oracle was not immediately available to explain the $15-million purchase, but a spokesman for San Ramon-based SuperGen said: "Larry has an interest in cancer, especially prostate cancer. A lot of his close friends like Michael Milken and [Intel Chairman] Andy Grove have had bouts with it."
November 30, 2000 |
NeoTherapeutics Inc., an Irvine biopharmaceutical company specializing in nerve regeneration research, said Wednesday that it has expanded its mission by forming a cancer therapy unit. The company said in a press release that it has named Dr. Luigi Lenaz, who has held executive positions at Bristol-Myers Squibb Co. for nearly 20 years, as president of the new unit, called NeoOncoRx.